SELLAS LIFE SCIENCES GROUP I (SLS) Stock Price, Quote, News and Summary

Company Profile

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of novel therapeutics for a range of cancer indications. The firm's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Company Info

SELLAS LIFE SCIENCES GROUP I

7 Times Square, Suite 2503

New York City NEW YORK 10018 US

CEO: Angelos M. Stergiou

Employees: 16

Company Website: https://www.sellaslifesciences.com/

Investor Relations: http://investors.galenabiopharma.com/investors/default.aspx

Phone: 16462005278